D87. Breast Conservation Therapy in The Augmented Woman

Abstract

PURPOSE: Annually, approximately 37,500 augmented women will develop breast cancer. Augmented women are often counseled to remove their implants if they plan to receive breast conservation therapy (BCT=lumpectomy + radiotherapy), for fear of an elevated complication rate and aesthetic dissatisfaction if the augmentation is maintained. We hypothesized that the complication and revision rates will be similar amongst augmented women who receive BCT with or without explantation. METHODS: A retrospective chart review was performed to identify all women who presented with a breast augmentation and a new diagnosis of breast cancer from 2016-2022. Women who opted to have a mastectomy were excluded. The primary outcomes were complication rate and revision rate. RESULTS: 160 women were included and the mean follow up was 2.9 years. All women received a lumpectomy and adjuvant radiotherapy. Fifty-nine women received an explantation combined with lumpectomy; 101 opted to maintain their augmentation. Amongst the 101 women who maintained augmentation, 34% kept their current implants and 66% underwent an implant exchange coincident with their lumpectomy. The overall complication and revision rates were 13% and 27%, respectively. There was no difference in the complication rate (8% vs. 15.8%: p=0.1) or revision rate (26.3% vs. 26.9%; p=1) between explanted and augmented women undergoing BCT. Multivariate logistic regression identified that an implant was not an independent predictor for complications (OR=2.4,95% CI.57-8.7;p=0.24) whereas surgical site infection was an independent predictor for revision (OR=10.2, 95% CI 1.4-75.5;p=0.02). CONCLUSION: Breast augmentation is not a contraindication to BCT.